Central nervous system trials have consistently shown among the highest failure rates of any therapeutic area, and a large share of that failure traces back not to ineffective drugs but to placebo response rates that have climbed steadily over the past two decades, narrowing the statistical window in which a genuine drug effect can be…
Central nervous system trials have consistently shown among the highest failure rates of any therapeutic area, and a large share of that failure traces back not to ineffective drugs but to placebo response rates that have climbed steadily over the past two decades, narrowing the statistical window in which a genuine drug effect can be detected.
Depression and pain trials illustrate the problem most clearly. Placebo response rates in major depressive disorder trials now frequently exceed 30 to 40 percent, driven by factors that have little to do with the biology of the condition itself, including trial site enthusiasm, frequent clinician contact built into the visit schedule, and patients’ own expectations shaped by trial enrollment materials.
Site-level variability in placebo response is often larger than variability between treatment arms, which means that site selection and site training have become as important to trial success as the underlying pharmacology. Sites with experienced raters using standardized assessment training tend to show more consistent, lower placebo response than sites with less rigorous rater calibration.
Adaptive and sequential parallel comparison designs have emerged specifically to address this issue, using a two-stage structure that re-randomizes placebo non-responders from the first stage into the second stage comparison, a method that can meaningfully improve a trial’s ability to detect a true drug effect against an inflated placebo baseline.
Rater training and centralized, blinded rating using video or audio review of assessment sessions has become standard practice in well-run CNS trials, specifically to reduce the site-level and rater-level variability that otherwise adds noise to symptom severity measurements and further obscures a genuine treatment signal.
Deep Dive coverage examining how specific CNS trial programs have structured their design to manage placebo response, rather than treating it as an unavoidable cost of doing business in the therapeutic area, such as the analysis published by The Clinical Trial Vanguard, gives trial designers in CNS indications a more concrete set of mitigation strategies to draw from.